We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sulopenem

News List

Iterum Therapeutics Announces NDA for Oral Sulopenem americanpharmaceuticalreview
January 29, 2021
Iterum Therapeutics announced the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in ...
Iterum hit by failure of anti-infective sulopenem pharmatimes
June 04, 2020
Shares in Dublin, Ireland and Chicago, US-based Iterum Therapeutics have taken a hit on news that the firm's sulopenem did not achieve statistical non-inferiority relative to ertapenem in a trial in complicated urinary tract infection (cUTI).